Research is the backbone of clinical practice, shaping medical advances in treatment and care.
Thopaz+ is the #1 clinical reference for digital drainage. For almost two decades, Medela has been paving the way for technological innovation in chest drain management, backed by an unparalleled body of clinical research. Over 65 studies involving more than 9,000 patients have demonstrated the significant benefits of Thopaz+ for enhancing patient outcomes and supporting evidence-based drainage protocols.
This research continues to grow, reinforcing the efficacy and safety of Thopaz+ in cardiothoracic care.
Explore our extensive clinical publication list and discover why Thopaz+ should be the gold standard for clinicians seeking proven solutions in digital chest drainage.